ANKAR PHARMA try to fill the investment gap between basic and clinical drug discovery research, concentrating in preclinical trials. Our strength is to combine excellent basic R&D results with business oriented decision making and results-oriented drug development. Alliances with other companies are actively pursuing by our team. Licenses agreements with up-front, milestones and/or royalties, or risk-sharing partnering are looking for.

426x224

MICHAEL DE JOSÉ, CHIEF EXECUTIVE OFFICER

426x224

Michael B. José, PhD is a Business consultant and a Lecturer in top Business Schools in Spain and other Countries (ESCP Europe, ESIC, Instituto de Empresa, European University of Madrid, Shanghai Business School, etc.)
He has an extensive experience in top management positions as Director and CEO in the last 30 years and has an international background in Europe, the US and Asia. He has a strong multidisciplinary approach due to his experience in several industries such as Consulting, Defense, Food, Biotechnology, Pharma Logistics, and Internet start-ups which has allowed him to bridge the gap between technical and innovative ideas and business success, delivering clear Return to investments. His experience in intrapreneurship and entepreneurship has proven in many cases that R&D and product innovation can translate into profitable business models.
He has a strong academic background, with Masters in Law and in Business Administration in Icade (Jesuits University in Spain). He has a General Management Degree in IESE -the top Business School in Spain-, a Specialized Program in Strategy in Cranfield Business School (UK), a Master in Auditing, and a PhD in Business Economics in European University in Madrid. A company founded by him was awarded as Innovative Logistic Company in 2002 by the Spanish ELA (European Logistics Association).

ANA MARTINEZ, CHIEF SCIENTIFIC OFFICER
426x224

Ana Martinez is Research Professor at the Biological Research Center (CIB) of Spanish National Council for Research (CSIC), having a background formation on Medicinal Chemistry. Her interest is focused on neurodegenerative disorders, leading numerous research projects on rational drug design and medicinal chemistry of new drugs for neurodegenerative diseases. Active areas of research involve among others, neurogenic drugs, and protein kinases, cAMP-specific phosphodiesterases, cholinesterases and proteases inhibitors. She has great experience in knowledge transfer from CSIC to the pharmaceutical sector. Since 2002 till 2008, to complete a technology transfer process, she joined to NeuroPharma, after named NOSCIRA, as R&D Director. She provided strategic, leadership management and guidance in R&D activities, reaching two of her research compounds, named NP-12 (tideglusib) and NP-61, clinical trials as disease modifying agents for Alzheimer’s disease. She is author of more than two hundred scientific publications, thirty active patents in the field and editor of several books. She acts as scientific advisory board for several SMEs in the biotech field and expert for national and international evaluation research grants. Several results from her research are currently under development by ARACLON BIOTECH and AUTISM THERAPUTICS. Recently, she is founder and CSO of ANKAR PHARMA, which goal is to full the gap between basic drug discovery research and clinical trials for neurodegenerative diseases effective pharmacological treatments.

CARMEN GIL, CHIEF RESEARCH OFFICER

426x224
Carmen Gil received her Ph.D. from Complutense University of Madrid in 2001 under the supervision of Prof. A. Martinez. After a postdoctoral appointment at Bonn University (Prof. Dr. Stefan Bräse), she joined the Medicinal Chemistry Institute (IQM-CSIC) in 2004 (first, as Associate Researcher and since 2007 as Staff Scientist) holding the responsibility of the design and synthesis of biologically active organic molecules in the neurodegenerative field. Her research areas have been focused on phosphodiesterase inhibitors as innovative drug candidates for neurological disorders. One of her molecules is currently in regulatory preclinical development to reach clinical trials for Parkinson’s disease by ARACLON BIOTECH. Since 2014 she moves to the Biological Research Center (CIB-CSIC) for advance her drug discovery projects being founder of ANKAR PHARMA.

JOSE MARIA OLBÉS, VICE PRESIDENT BUSSINESS DEVELOPMENT

426x224
Mr. Olbes is Business Development VP for Ankar Pharma SL. His early years of work centered mainly in both the corporate and the banking sector, and his international banking experience came with private banking stints in London with Citibank, and in Geneva with the Dresdner Bank. During the last 10 years, he has been doing client advisory work with the Deutsche Bank. After a career in banking, he has chosen to transition to the biotechnology sector (within Spain), and is one of five founders of a Madrid-based biotech, focused on developing drugs to counter neurodegenerative pathologies. His new role will require the designing and coordinating of all strategy with regards public entities, foundations, banks, private equity, angel investors, etc.
Mr. Olbes received his Bachelor of Science degree in Economics from the College of the Holy Cross in Worcester, Massachusetts, and an M.B.A. from Columbia University in New York City, New York.

JOEY LEVISTE III, LEGAL COUNSELOR
426x224